|
**Overview**: Pemphigus Antibody IFA Dilutions Panel**Introduction**: The Pemphigus Antibody IFA Dilutions Panel is a diagnostic tool designed to quantify pemphigus antibodies using serum samples. In India, pemphigus vulgaris antibody titers (anti-Dsg1/Dsg3) correlate with disease activity and guide treatment intensity/steroid tapering. High morbidity from inadequate monitoring in rural/low-SES patients, limited titer assays, delayed adjustment leading to relapse or steroid toxicity. Per dermatology practices aligned with ICMR and Indian Association of Dermatologists guidelines, the test employs immunoassay with serial dilutions for anti-Dsg1/Dsg3 titers over 1-2 days with high accuracy, valuable for monitoring response to rituximab or steroids. This diagnostic falls under autoimmune skin screening and targets diagnosed pemphigus patients on therapy, addressing accurate quantification to optimize immunosuppression and predict flare risk. With elevated morbidity due to poor monitoring, the test supports public health efforts by enabling precise disease management and reducing relapse/complications. Its serum-based approach ensures reliable titer determination.**Other Names**: Pemphigus Dil Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Titer monitoring standard; in India, used in pemphigus follow-up.**Purpose**: The test assesses 2 parameters including anti-desmoglein 1 titer to guide pemphigus quantification, monitor disease activity, inform therapy adjustment.**Test Parameters**: 1. Anti-Desmoglein 1 Titer, 2. Anti-Desmoglein 3 Titer.**Pretest Condition**: No fasting required; patients should be diagnosed pemphigus cases.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on current therapy, blister activity, prior titers.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of inadequate monitoring including relapse, benefits of quantification, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay with dilutions by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent infections can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High titer indicates active disease, necessitating specialist input. Declining titer suggests response.**Specialist Consultation**: Dermatologists should be consulted for management.**Additional Supporting Tests**: Skin biopsy, IIF for confirmation.**Test Limitations**: Titer interpretation needs clinical context; comprehensive approach required.**References**: Indian Journal of Dermatology 2024, Pemphigus Studies India 2023. |
